Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

The role of temozolomide in the treatment of a patient with a pure silent pituitary somatotroph carcinoma.

Vieira Neto L, Chimelli L, Pereira PJ, Gasparetto EL, Bines J, Wildemberg LE, Gadelha MR.

Endocr Pract. 2013 Nov-Dec;19(6):e145-9. doi: 10.4158/EP12400.CR.

PMID:
23807517
2.

Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa.

Maiza JC, Vezzosi D, Matta M, Donadille F, Loubes-Lacroix F, Cournot M, Bennet A, Caron P.

Clin Endocrinol (Oxf). 2007 Aug;67(2):282-9. Epub 2007 May 24.

3.

Short-term preoperative octreotide treatment of GH-secreting pituitary adenoma: predictors of tumor shrinkage.

Oshino S, Saitoh Y, Kasayama S, Arita N, Ohnishi T, Kohara H, Izumoto S, Yoshimine T.

Endocr J. 2006 Feb;53(1):125-32.

4.

Treatment of invasive silent somatotroph pituitary adenoma with temozolomide. Report of a case and review of the literature.

Ghazi AA, Rotondo F, Kovacs K, Amirbaigloo A, Syro LV, Fathalla H, Di Ieva A, Cusimano MD.

Endocr Pathol. 2015 May;26(2):135-9. doi: 10.1007/s12022-015-9361-z. Review.

PMID:
25716461
5.
6.

Five-year follow-up of a 13-year-old boy with a pituitary adenoma causing gigantism--effect of octreotide therapy.

Schoof E, Dörr HG, Kiess W, Lüdecke DK, Freitag E, Zindel V, Rascher W, Dötsch J.

Horm Res. 2004;61(4):184-9. Epub 2004 Jan 23.

PMID:
14739526
7.

Long-term octreotide therapy in growth hormone-secreting pituitary adenomas: evaluation with serial MR.

Lundin P, Edén Engström B, Karlsson FA, Burman P.

AJNR Am J Neuroradiol. 1997 Apr;18(4):765-72.

8.

Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?

Jallad RS, Musolino NR, Kodaira S, Cescato VA, Bronstein MD.

Clin Endocrinol (Oxf). 2007 Aug;67(2):310-5. Epub 2007 Jun 6.

PMID:
17555503
9.

Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly.

Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, Lancranjan I, Lombardi G.

J Clin Endocrinol Metab. 2001 Jun;86(6):2779-86.

PMID:
11397887
10.

A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly.

Mercado M, Borges F, Bouterfa H, Chang TC, Chervin A, Farrall AJ, Patocs A, Petersenn S, Podoba J, Safari M, Wardlaw J; SMS995B2401 Study Group.

Clin Endocrinol (Oxf). 2007 Jun;66(6):859-68. Epub 2007 Apr 25.

11.

First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial.

Colao A, Pivonello R, Rosato F, Tita P, De Menis E, Barreca A, Ferrara R, Mainini F, Arosio M, Lombardi G.

Clin Endocrinol (Oxf). 2006 Mar;64(3):342-51.

PMID:
16487447
12.

Eight-year follow-up of a child with a GH/prolactin-secreting adenoma: efficacy of pegvisomant therapy.

Bergamaschi S, Ronchi CL, Giavoli C, Ferrante E, Verrua E, Ferrari DI, Lania A, Rusconi R, Spada A, Beck-Peccoz P.

Horm Res Paediatr. 2010;73(1):74-9. doi: 10.1159/000271919. Epub 2010 Jan 15.

PMID:
20190543
13.

Octreotide as primary therapy for acromegaly.

Newman CB, Melmed S, George A, Torigian D, Duhaney M, Snyder P, Young W, Klibanski A, Molitch ME, Gagel R, Sheeler L, Cook D, Malarkey W, Jackson I, Vance ML, Barkan A, Frohman L, Kleinberg DL.

J Clin Endocrinol Metab. 1998 Sep;83(9):3034-40.

PMID:
9745397
14.

Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR.

Jenkins PJ, Emery M, Howling SJ, Evanson J, Besser GM, Monson JP.

Horm Res. 2004;62(5):227-32. Epub 2004 Oct 11.

PMID:
15477693
15.

Aggressive silent GH pituitary tumor resistant to multiple treatments, including temozolomide.

Batisse M, Raverot G, Maqdasy S, Durando X, Sturm N, Montoriol PF, Kemeny JL, Chazal J, Trouillas J, Tauveron I.

Cancer Invest. 2013 Mar;31(3):190-6. doi: 10.3109/07357907.2013.775293.

PMID:
23477586
16.

Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size.

Bevan JS, Atkin SL, Atkinson AB, Bouloux PM, Hanna F, Harris PE, James RA, McConnell M, Roberts GA, Scanlon MF, Stewart PM, Teasdale E, Turner HE, Wass JA, Wardlaw JM.

J Clin Endocrinol Metab. 2002 Oct;87(10):4554-63.

PMID:
12364434
17.

Effect of temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma.

Syro LV, Scheithauer BW, Ortiz LD, Fadul CE, Horvath E, Rotondo F, Kovacs K.

Hormones (Athens). 2009 Oct-Dec;8(4):303-6.

18.

Effect of preoperative use of long-acting octreotide on growth hormone secreting pituitary adenoma and transsphenoidal surgery.

Yin J, Su CB, Xu ZQ, Yang Y, Ma WB, Tao W, Yang Z, Xia XW.

Chin Med Sci J. 2005 Mar;20(1):23-6.

PMID:
15844307
19.

Thyrotropin secreting pituitary adenoma accompanying a silent somatotropinoma.

Berker D, Isik S, Aydin Y, Tutuncu Y, Akdemir G, Ozcan HN, Guler S.

Turk Neurosurg. 2011;21(3):403-7. doi: 10.5137/1019-5149.JTN.2642-09.2.

20.

Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.

Plöckinger U, Quabbe HJ.

Acta Neurochir (Wien). 2005 May;147(5):485-93; discussion 493. Epub 2005 Apr 4.

PMID:
15806331

Supplemental Content

Support Center